Versant Capital Management’s Immunome IMNM Stock Holding History

Versant Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$495	Buy	+23	New	+$571	﹤0.01%	2757
2025 Q2	–	Sell	-1,170	Closed	-$7.87K	–	2678
2025 Q1	$7.87K	Buy	+1,170	New	+$11.2K	﹤0.01%	1837

Other funds holding IMNM

MWM

Maltin Wealth Management Ridgewood, New Jersey $308M AUM 16.5% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Versant Capital Management's IMNM Position: Q3 2026 in Review

Versant Capital Management opened a new position in Immunome (IMNM) in Q3 2026: 23 shares worth $495. The stake represents ﹤0.01% of the portfolio and ranks #2757 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in IMNM as recently as Q1 2025.

Versant Capital Management first reported a position in IMNM in Q1 2025 and has held it in 2 quarters since. The position peaked at $7.87K in Q1 2025. 6 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

Versant Capital Management held 23 shares of Immunome worth $495 as of Q3 2026.
Immunome was a new Versant Capital Management position in Q3 2026.
Immunome made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2757 holding.
Versant Capital Management first reported a position in Immunome in Q1 2025 and has held it in 2 quarters since.
Versant Capital Management's Immunome position peaked at $7.87K in Q1 2025.
6 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.